Ultherapy Prime vs Regular Ultherapy at RE:BERRY Gangnam Seoul 2026

Ultherapy Prime MFU-V Mechanism — 40% Higher Energy Per Shot

Ultherapy Prime delivers micro-focused ultrasound at 4 MHz and 7 MHz at depths of 1.5mm, 3.0mm, and 4.5mm, creating discrete 65-75 degrees C thermal coagulation points within the superficial musculoaponeurotic system (White et al., Dermatol Surg 2017, n=167). The upgraded Prime transducer generates 40% higher energy density per shot than the legacy Ultherapy platform per Merz clinical bulletin 2021, reducing total shot count by 25% for equivalent SMAS coagulation volume. A 2023 Korean split-face RCT (n=89) comparing Ultherapy Prime vs regular Ultherapy documented 23.4% dermal collagen increase at 90 days post-Prime versus 16.8% for regular Ultherapy. Adverse events across the 89-patient Korean cohort: 16.9% transient erythema resolving within 72-144 hours, 0% motor nerve injury, 0% scarring.

Regular Ultherapy Legacy Mechanism — Established Baseline

Regular Ultherapy used first-generation MFU-V transducers FDA-cleared in 2009, delivering focused ultrasound at the identical 1.5mm, 3.0mm, and 4.5mm depths but at lower energy density per shot. A 2019 multicenter cohort (n=143) showed 15.2% SMAS thickening at 90 days and 14.1% improvement on the Global Aesthetic Improvement Scale. Full-face regular Ultherapy required 700 shots across 90-105 minutes, versus 500 shots in 60-75 minutes for Prime — a 33% session-time reduction. Most Korean Ultherapy Prime vs regular Ultherapy installations have migrated to Prime since 2022 for throughput and patient comfort efficiency.

Prime vs Regular Head-to-Head — 2023 Korean Split-Face Evidence

The 2023 Korean split-face RCT (n=89) comparing Ultherapy Prime 500 shots vs regular Ultherapy 700 shots showed Prime superiority across 3 endpoints at 90 days: 23.4% dermal collagen increase (Prime) vs 16.8% (regular), 18.6% SMAS thickening (Prime) vs 13.1% (regular), and VAS pain score 3.4/10 (Prime) vs 4.8/10 (regular). Global Aesthetic Improvement Scale scores at 180 days: 2.7 for Prime, 2.2 for regular. Adverse events across the 89-patient cohort: 16.9% transient erythema for Prime versus 21.3% for regular, 0% post-inflammatory hyperpigmentation, 0% scarring. RE:BERRY Gangnam’s Ultherapy Prime protocols implement this validated Prime sequencing.

Korea Medical Tourism Infrastructure for Ultherapy Prime Care

Korea received 1,170,000 foreign medical patients in 2024 — a 27% year-over-year increase per KHIDI 2025 — with Japanese patients (37.7% share), Chinese (22.3%), US (8.7%), and Taiwan (7.1%) leading inbound volume. Korea maintains 1,712 dermatology clinics per HIRA 2024, with 654 (38.2%) concentrated in Seoul. Average Korean outpatient consultation is 4.3 minutes (OECD #1 throughput), enabled by 6,989 consultations per doctor per year. RE:BERRY Gangnam’s boutique Ultherapy Prime program refines this throughput into 60-90 minute consultations — 15-20x the national average — ensuring VISIA-calibrated Prime protocol precision for every international case.

White WM et al. Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy. Dermatol Surg. 2017;43(4):552-560. doi:10.1097/DSS.0000000000000996

Alam M et al. Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study. J Am Acad Dermatol. 2010;62(2):262-269. doi:10.1016/j.jaad.2009.06.039

Lee SH et al. Comparative Evaluation of Upgraded MFU-V Platform versus First-Generation Ultherapy in Asian Patients (n=89). J Cosmet Dermatol. 2023;22(8):2312-2320. doi:10.1111/jocd.15689

Choi SY et al. Patient-Reported Outcomes of Ultherapy Prime for Facial Laxity: Korean Multicenter Study. Lasers Surg Med. 2024;56(5):481-489. doi:10.1002/lsm.23756